GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » Capital Expenditure

Prestige Biologics Co (XKRX:334970) Capital Expenditure : ₩-4,463.71 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige Biologics Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Prestige Biologics Co's cash flow for capital expenditures for the three months ended in Sep. 2024 was ₩-1,268 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was ₩-4,463.71 Mil.

Prestige Biologics Co Capital Expenditure Historical Data

The historical data trend for Prestige Biologics Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Biologics Co Capital Expenditure Chart

Prestige Biologics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Jun23 Jun24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -3,051.42 -98,011.23 -84,789.84 -19,495.36 -8,637.14

Prestige Biologics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,441.81 1,827.15 -669.60 -4,352.88 -1,268.38

Prestige Biologics Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-4,463.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prestige Biologics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » Capital Expenditure
Comparable Companies
XKRX:216080 XKRX:115450 XKRX:228760 XKRX:199800 XKRX:095700 XKRX:397030 XKRX:048870 XKRX:053030 XKRX:011000 XKRX:060590 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
197, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Chungcheongbuk-do, Cheongju-si, KOR, 28161
Website
https://www.prestigebiologics.com
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).

Prestige Biologics Co Headlines

No Headlines